InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,459.10
(
1.11%
)
US TECH 100
18,514.00
(
1.00%
)
Dow Jones
40,589.34
(
1.64%
)
Brent Oil
80.78
(
0.25%
)
Bitcoin
69,692.79
(
2.08%
)
Post# of 651527
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

tw0122

Send PM Follow Ignore
Followers 189
Posts 22683
Boards Moderated 0
Alias Born 08/14/2011

tw0122

Re: None

Thursday, 06/20/2024 10:10:35 AM

Thursday, June 20, 2024 10:10:35 AM

Post# of 651527
IBRX $7.31 + 17% 09:45 AM EDT,06/20/2024 (MT Newswires) -- ImmunityBio (IBRX) said Thursday that it has launched Anktiva, its immunotherapy to treat Bacillus Calmette-Guerin-unresponsive non-muscle invasive bladder cancer, with multiple patients across the US receiving the initial commercial doses.

The US Food and Drug Administration approved Anktiva in April to treat patients with BCG-unresponsive non-muscle invasive bladder cancer with or without papillary tumors, according to ImmunityBio.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up